Abstract 77P
Background
Sexual dysfunction is of the most common late effects after cancer. Normative general population data on sexual health is essential for supporting the interpretation of patient-reported outcomes (PROMs) in cancer studies and clinical practice and can contribute to improve survivorship care. This study aims to provides age-, sex- and morbidity specific Norwegian normative values for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires; the Sexual Health Questionnaire QLQ-SHQ22, and the sexual domains of the breast modules QLQ-BR23/QLQ-BR45 inindividuals with and without history of cancer.
Methods
A nationwide general population sample stratified by sex and age (18–29, 30–39, 40–49, 50–59, 60–69, 70-79 years) was drawn from the Norwegian Population Register. Participants were notified through National online health services and postal mail. The survey included sociodemographic background, morbidity assessed bythe Self-Administered Comorbidity Questionnaire and sexual health assessed by the sexual health EORTC questionnaires.
Results
Of the 15,627 eligible individuals, 5,135 (33%) responded. Among these, 453 persons reported being diagnosed one or several times with cancer, and 4669 persons had no former history of cancer (breast, prostate, gynecological and others). Individuals with cancer scored significantly lower (p<0.01) on several functional scales: libido (scores 54 vs. 70), sexual functioning (45 vs 58), sexual enjoyment (67 vs 76), and for women femininity (65 vs. 84). The most prominent differences in symptoms were fatigue (32 vs 20) and worry of incontinence (27 vs. 9). Women and individuals with comorbidities had in general poorer sexual health, and differences were most pronounced in the youngest age groups.
Conclusions
The present study is the first to use normative EORTC data to compare sexual health in individuals with- and without cancer. Sexual health was in general significantly poorer in individuals with history of cancer compared to individuals without cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Randi Johansen Reidunsdatter.
Funding
Norwegian Cancer Society and Norwegian Breast Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Cold atmospheric plasma-activated fluids as a potential new intravesical agent for the treatment of bladder cancer
Presenter: Maria Filomena Botelho
Session: Poster session 09
90P - Discovery of CMPD1 as a tumor-specific cytotoxic microtubule inhibitor
Presenter: Mamoru Takada
Session: Poster session 09
91P - Erythroid precursor-differentiated myeloid cells promote pulmonary metastasis in hepatocellular carcinoma
Presenter: Wei-hang Zhu
Session: Poster session 09
92P - Discovery of novel AXL and MER inhibitors as potential anticancer and immune modulator drugs
Presenter: Hsing-Pang Hsieh
Session: Poster session 09
93P - Transcriptome changes of immune cells across chemotherapy of triple-negative breast cancer
Presenter: Tatiana Gerashchenko
Session: Poster session 09
509P - Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Presenter: Markus Kleinberger
Session: Poster session 09
510P - CD47 regulates cellular and metabolic plasticity in glioblastoma
Presenter: Ruhi Polara
Session: Poster session 09
511P - Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Presenter: Santiago Cabezas-Camarero
Session: Poster session 09
512P - Heterozygous germline Fanconi anemia-related gene mutations increase susceptibility to central nervous system germ cell tumors
Presenter: Guangyu Wang
Session: Poster session 09
513P - Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 09